Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Study to Assess the Safety of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease Who Completed C87035 (NCT00899678) or Who Were Terminated From C87035

NCT01190410 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT01190410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01190410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Study to Assess the Safety of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease Who Completed C87035 (NCT00899678) or Who Were Terminated From C87035
Lead sponsor
UCB Pharma
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
November 27, 2017
Enrollment
16 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease